PHOTO
UK based Medovate – a dynamic medical device development company specialising in anesthesia, airway management, critical care, and surgery – has today announced its first agreement in the Middle East with Omneya Medical Co. to distribute SAFIRA™ (SAFer Injection for Regional Anesthesia) in Kuwait.
Developed in collaboration with clinicians from the National Health Service (NHS) in the UK, SAFIRA™ is a revolutionary Class II medical device set to transform regional anesthesia around the world by making it a one-person procedure.
It puts control of the injection in the hands of the anesthesiologist, freeing up other staff to carry out other tasks. The device also helps to improve patient safety by reducing the risk of nerve damage as it automatically limits injection pressure to less than 20psi.
Despite the ongoing global COVID-19 pandemic, which has resulted in strict border closures worldwide, Medovate has successfully secured a deal bringing the significant benefits SAFIRA™ provides to the regional anesthesia market in Kuwait.
One of the fast-growing companies in the country, Omneya Medical Co’s vision is to bring novel innovations to medical systems that support improvements in patient safety and care, a philosophy that aligns well with Medovate and the foundations on which SAFIRA™ was developed.
Chris Rogers, Sales and Marketing Director, Medovate, commented: “Securing this agreement with Omneya Medical is a great achievement, and as our first distribution partner in the Middle East allows us to start positioning the many benefits SAFIRA™ brings to both patients and clinicians in Kuwait.”
Mr Jarrah Al Mutairi, Managing Director at Omneya Medical Co., added: “We are pleased to enter this strategic agreement with Medovate, which will be the beginning of further cooperation between our companies. I’m happy that clinicians and patients in Kuwait are the first in the Middle East to utilise the advantages offered by SAFIRA™ and I would like to thank the Medovate team for their efforts”.
SAFIRA™ has the potential to make a significant impact by turning regional anesthesia into a one-person procedure. Recent publications, including a joint statement by the American Society of Regional Anesthesia and Pain Management (ASRA) and the European Society of Regional Anesthesia and Pain Therapy (ESRA), have recommended regional anesthesia be considered whenever surgery is planned for a suspected or confirmed COVID-19 patient. This is because it preserves respiratory function and avoids aerosolization and the potential for transmission of COVID-19 compared to general anesthesia.
As demand for such procedures continues to grow steadily SAFIRA™ has the potential to make a significant impact in areas such as the Middle East, where the anaesthesia devices market is set to experience further growth in the next five years.
Providing additional clinical advocacy in the Middle East is Consultant Anesthesiologist Dr Emad Fawzy, a co-inventor of SAFIRA™ who is currently based at the flagship Sheikh Khalifa Medical City in Abu Dhabi. He was previously based at the Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust in the UK as part of the team of clinical specialists behind the pioneering device. Medovate is dedicated to working closely with both the National Health Service (NHS) and clinicians in the UK to identify, develop and commercialize innovative medical devices with a focus on improving patient safety on a global scale.
-Ends-
For further information or visuals of SAFIRA® please contact: Julia Price julia.price@medovate.co.uk
About Medovate www.medovate.co.uk
Medovate is a medical device company dedicated to the development and commercialisation of innovative medical technologies created within the NHS and beyond. Medovate identifies and works with high potential medtech innovations, providing the specialist management and technical resources, along with finance required to lead innovation development through clinical trials and regulatory approval. By providing funding and support at a crucial point in the development of innovative medical technologies, Medovate accelerates innovations to market in order to benefit patient care and healthcare delivery. The company has a strong portfolio relating to specialisms in anaesthesia, airway management, critical care and surgery. Medovate directly benefits the NHS by:
- Providing access to funding, support and expertise to enable innovations created within the NHS to reach the market
- Delivering commercial returns to the NHS organisations and inventors that created the technologies
About Omneya Medical Co www.omnemed.com
OMNEMED is a Kuwait based company specialized in distribution of medical equipment and supplies, collaboration with leading international partners to offer the latest technologies and solutions that satisfy the needs and requirements of healthcare sector through well trained professionals that are capable of supporting and delivering.
The Company provides wide range of products from different categories to satisfy customers needs in Ministry of Health, Private Hospitals, Medical Centres and Pharmacies.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
